Process for the preparation of thalidomide
CA 2626178 A1 · Owner: Celgene Corporation · Inventors: Muller, George W.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compounds which are useful for reducing levels of TNF.alpha. in a mammal. Examples of compounds include those of formula: , wherein, for example, R7 is a cyclic alkyl a , substituted phenyl, etc ...; n is 1 and R12 is an alkoxy a , disubstituted amino, etc ...;, those of formula: wherein, for example, Z is, or R4 NH-, n is 1 2 or 3;, R1 is a divalent residue of 3,4-pyridine pyrrolidine, etc ...;, R2 is -CO- or -SO2-; R3 is a substituted phenyl pyridyl, etc ...; and R4 is alanyl, argynyl etc.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 1, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 1, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 1, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.